Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Interim Phase II Telaprevir Data Point To Possible Shortened Hep C Treatment Course

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Vertex hopes to base Phase III trial design on 12-week dosing with telaprevir plus standard of care followed by standard of care for 12 weeks.

You may also be interested in...



Vertex Telaprevir NDA In Treatment-Naïve Hep C Now Planned For 2010

Firm expects data from pivotal 24-week trials in mid-2010.

Vertex Telaprevir NDA In Treatment-Naïve Hep C Now Planned For 2010

Firm expects data from pivotal 24-week trials in mid-2010.

Telaprevir Phase IIb Data Continues To Support 24-Week Dosing For Hepatitis C, Vertex Says

PROVE-2 data show 65 percent sustained viral response in treatment naive patients, Vertex reports.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

See All
UsernamePublicRestriction

Register

PS065903

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By